4.1 Diabetes Mellitus & Endocrine Emergencies

4.1 Diabetes Mellitus & Endocrine Emergencies

Core Clinical Rule: In the emergency management of Diabetic Ketoacidosis (DKA), never administer an insulin bolus or start an insulin infusion if the serum potassium is < 3.3 mmol/L; potassium must be aggressively replaced first to prevent fatal ventricular arrhythmias and respiratory arrest. Furthermore, when plasma glucose falls below 14.0 mmol/L, intravenous fluids must immediately be transitioned to 5% Dextrose in 0.9% Normal Saline to prevent rapid osmotic fluid shifts across the blood-brain barrier and catastrophic cerebral edema.

Endocrine and metabolic disorders represent a significant proportion of acute medical admissions and chronic outpatient visits across Kenyan healthcare facilities. According to the Kenya National STEPwise Survey for Non-Communicable Diseases (NCDs), the national adult prevalence of diabetes mellitus is approximately 3.3%, with over 60% of affected Kenyans remaining undiagnosed until presenting with advanced microvascular or life-threatening acute metabolic decompensation. For the Clinical Officer intern, mastery of diagnostic thresholds, oral and injectable regimens, renal precautions, and acute endocrine resuscitation algorithms is foundational for clinical practice and national licensure.

---

1. Kenya National Guidelines for the Diagnosis of Diabetes Mellitus

Standard Diagnostic Criteria

According to the Kenya National Guidelines for the Prevention and Management of Non-Communicable Diseases (Ministry of Health), the diagnosis of Diabetes Mellitus is confirmed when any one of the following criteria is met on venous plasma:

Clinical Testing Pearls:

• Fasting is defined as no caloric intake for at least 8 hours.
• In the absence of unequivocal symptomatic hyperglycemia (classic osmotic triad of polyuria, polydipsia, and unexplained weight loss) or acute hyperglycemic crisis, a single abnormal laboratory test must be confirmed by repeat testing on a subsequent day using a fresh venous blood sample.
• Capillary point-of-care glucometer strips are recommended for screening and monitoring; however, venous plasma laboratory confirmation is the standard for formal diagnosis.
• HbA1c must be measured using a method certified by the National Glycohemoglobin Standardization Program (NGSP). In conditions with altered erythrocyte turnover (e.g., sickle cell anemia, severe malaria, pregnancy, recent blood transfusion, end-stage renal disease), HbA1c is unreliable, and plasma glucose criteria must be used exclusively.

---

2. Outpatient Pharmacotherapy of Type 2 Diabetes Mellitus

                    [Newly Diagnosed Type 2 Diabetes Mellitus]
                                       |
                   +-------------------+-------------------+
                   |                                       |
           [HbA1c < 8.5% and                       [HbA1c >= 8.5% or
          Symptomatically Stable]                 Symptomatic / Catabolic]
                   |                                       |
        [Lifestyle Intervention]                [Lifestyle Intervention]
                   +                                       +
        [Metformin Monotherapy]                 [Dual Therapy: Metformin +
         500 mg daily, titrate                   Sulfonylurea / SGLT2i / Basal Insulin]
         to 1000 mg BID (max 2000 mg)                      |
                   |                                       |
                   v                                       v
       [Review at 3 Months]                    [Review at 3 Months]
       Target HbA1c < 7.0%                     Target HbA1c < 7.0%
                   |
       +-----------+-----------+
       |                       |
  [At Target]             [Not at Target (HbA1c >= 7.0%)]
       |                       |
Continue Current        Add Second Agent:
Regimen                 • Sulfonylurea (Gliclazide / Glimepiride)
                        • SGLT2i (Empagliflozin / Dapagliflozin)
                        • Basal Insulin (10 units or 0.1-0.2 U/kg)

Foundational Oral Antidiabetic Classes

1. Biguanides (Metformin):

   • Dosing & Administration: Initiate at 500 mg PO once daily with the evening meal. Titrate upward by 500 mg every 1 to 2 weeks to a target therapeutic dose of 1000 mg PO twice daily (maximum effective dose 2000–2550 mg daily). Administration with meals minimizes common gastrointestinal adverse effects.
   • Mechanism of Action: Activates AMP-activated protein kinase (AMPK), leading to decreased hepatic gluconeogenesis, decreased intestinal absorption of glucose, and enhanced peripheral insulin sensitivity in skeletal muscle.
   • Clinical Placement: The universal first-line pharmacological agent for all newly diagnosed Type 2 diabetes patients without contraindications. It is weight-neutral, does not cause hypoglycemia as monotherapy, and provides proven cardiovascular risk reduction.
   • Renal Precautions & Contraindications:
     • eGFR $\ge 60\text{ mL/min}$: Full dose permitted (up to 2000 mg/day); monitor renal function annually.
     • eGFR $45 - 59\text{ mL/min}$: Continue full or moderate dose; monitor renal function every 3 to 6 months.
     • eGFR $30 - 44\text{ mL/min}$: Reduce maximum dose by 50% (maximum 1000 mg daily); do not initiate new patients.
     • eGFR $< 30\text{ mL/min}$: Strictly contraindicated due to impaired drug clearance leading to Metformin-Associated Lactic Acidosis (MALA).
     • Peri-procedural Holding: Withhold Metformin 48 hours prior to iodinated radiocontrast procedures or major surgery, resuming 48 hours post-procedure only after reconfirming stable renal function.

2. Sulfonylureas (Gliclazide, Glimepiride):

   • Agents & Dosages: Gliclazide modified-release (MR) 30–120 mg PO once daily with breakfast; Glimepiride 1–4 mg PO once daily.
   • Mechanism: Binds to the sulfonylurea receptor (SUR1) on pancreatic beta-cell membranes, blocking ATP-sensitive $K^+$ channels, depolarizing the cell membrane, opening voltage-gated $Ca^{2+}$ channels, and stimulating glucose-independent insulin exocytosis.
   • Clinical Placement: Cost-effective second-line add-on therapy when Metformin monotherapy fails to achieve the target HbA1c ($< 7.0%$) within 3 months, or first-line if Metformin is contraindicated.
   • Safety Warning: Glibenclamide is strongly discouraged in the elderly and patients with mild-to-moderate renal impairment due to active metabolites with prolonged half-lives causing severe, protracted hypoglycemia. Gliclazide and glimepiride have lower hypoglycemia risk.

3. Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors (Empagliflozin, Dapagliflozin):

   • Agents & Dosages: Empagliflozin 10–25 mg PO once daily; Dapagliflozin 10 mg PO once daily.
   • Mechanism: Selectively inhibits SGLT2 in the proximal convoluted renal tubule, blocking glucose and sodium reabsorption, thereby inducing glucosuria (excreting 60–80 g glucose/day) and osmotic natriuresis.
   • Clinical Placement: Compelling indication for patients with established atherosclerotic cardiovascular disease, heart failure with reduced ejection fraction (HFrEF), or diabetic kidney disease (proteinuria / microalbuminuria).
   • Adverse Effects: Vulvovaginal candidiasis, mycotic balanitis, urinary tract infections, volume depletion/orthostatic hypotension, and rare euglycemic Diabetic Ketoacidosis (euDKA) (DKA with normal or minimally elevated blood glucose levels, often triggered by acute illness, surgery, or dehydration).

Initiation of Insulin Therapy in Type 2 Diabetes

• Indications for Insulin Initiation: Severe symptomatic hyperglycemia (FPG $> 15.0\text{ mmol/L}$, HbA1c $> 10.0%$, ketonuria, unintended rapid weight loss), failure of dual or triple oral therapy, acute intercurrent illness (sepsis, acute myocardial infarction, major surgery), or pregnancy.
• Initiation Protocol: Begin with Basal Insulin (Intermediate-acting NPH insulin or long-acting analog Glargine/Detemir) at 10 units daily at bedtime, or weight-based dosing at 0.1 to 0.2 units/kg/day.
• Titration Algorithm: Instruct the patient to check fasting blood glucose daily. Increase the basal dose by 2 units every 3 days until the fasting capillary glucose reaches the target range of 4.4 to 7.0 mmol/L. If fasting hypoglycemia occurs ($< 4.0\text{ mmol/L}$), reduce the basal dose by 4 units or 10%.

---

3. Diabetic Ketoacidosis (DKA) vs Hyperosmolar Hyperglycemic State (HHS)

Pathophysiologic Differences

        [DIABETIC KETOACIDOSIS (DKA)]              [HYPEROSMOLAR HYPERGLYCEMIC STATE (HHS)]
                      |                                               |
       [ABSOLUTE Insulin Deficiency]                   [RELATIVE Insulin Deficiency]
                      |                                (Sufficient to suppress lipolysis,
       [Massive Counter-Regulatory                      insufficient for glucose uptake)
        Hormone Surge: Glucagon,                                      |
        Epi, Cortisol, GH]                                  [Extreme Hyperglycemia
                      |                                      > 33.3 mmol/L (> 600 mg/dL)]
       +--------------+--------------+                                |
       |                             |                     [Massive Osmotic Diuresis]
[Accelerated Lipolysis]     [Severe Hyperglycemia]                    |
       |                     > 14.0 mmol/L                 [Profound Dehydration
[Free Fatty Acid Influx]             |                      (Fluid deficit 8-10 Liters)]
       |                    [Osmotic Diuresis                         |
[Hepatic Ketogenesis]        Fluid Deficit 4-6 L]          [Extreme Hyperosmolality
(Beta-hydroxybutyrate &              |                      > 320 mOsm/kg]
 Acetoacetate)]                      |                                |
       |                             v                     [Altered Sensorium / Stupor]
       v                    [Electrolyte Wasting:                     |
vvvvvvvvvvvvvvvvvvvv         K+, Na+, Phos, Mg]            (NO Significant Ketosis / Acidosis)
[HIGH ANION GAP METABOLIC ACIDOSIS (pH < 7.30, HCO3 < 15, AG > 12)]

Diagnostic Differentiation Table

Formula for Effective Serum Osmolality:
$\text{Effective Osmolality (mOsm/kg)} = 2 \times [\text{Na}^+ \text{ (mmol/L)}] + [\text{Glucose (mmol/L)}]$

---

4. Stepwise Emergency DKA Resuscitation Protocol

Management of DKA rests on four synchronized pillars: aggressive fluid rehydration, low-dose regular insulin, vigilant potassium replacement, and identification of the precipitating trigger (infections [pneumonia, UTI], missed insulin doses, acute myocardial infarction, cerebrovascular events, trauma, or pregnancy).

Pillar 1: Fluid Resuscitation Protocol

Severe dehydration and hypovolemia are universal. Restoring intravascular volume is the absolute priority to reduce counter-regulatory hormone levels and restore renal perfusion:

• Hour 1: Administer 1000 mL of 0.9% Normal Saline (0.9% NaCl) IV over the first hour (15–20 mL/kg/hr).
• Hours 2 and 3: Infuse 1000 mL of 0.9% Normal Saline over each subsequent hour (if severe shock persists, infuse faster; if heart failure present, adjust cautiously).
• Hours 4 through 8: Infuse 500 mL/hr of 0.9% Normal Saline (or 0.45% Saline if corrected serum sodium is normal or elevated).
• Subsequent Infusion: 250–500 mL/hr guided by hemodynamic parameters, urine output (target $> 0.5\text{ mL/kg/hr}$), and tissue turgor.
• THE CRITICAL GLUCOSE THRESHOLD (14.0 mmol/L): When plasma glucose drops to below 14.0 mmol/L (250 mg/dL), immediately change IV fluids to 5% Dextrose in 0.9% Normal Saline (or 5% Dextrose in 0.45% Saline) and adjust the insulin infusion rate to 0.05 units/kg/hr. This maintains plasma glucose between 8.0 and 12.0 mmol/L while continuing insulin to clear circulating ketoacids, preventing catastrophic brain edema and hypoglycemia.

Pillar 2: Regular (Soluble) Insulin Therapy

• Pre-requisite Check: Confirm serum potassium is $\ge 3.3\text{ mmol/L}$ before giving any insulin!
• Continuous Infusion Regimen (Preferred): Administer Regular (Soluble) Insulin IV infusion at a fixed rate of 0.1 units/kg/hour (e.g., 7 units/hr for a 70 kg patient). An initial IV bolus of 0.1 units/kg is optional, but if omitted, start infusion at 0.14 units/kg/hr.
• Monitoring Target: Blood glucose should decrease by 3.0 to 4.0 mmol/L per hour (50–70 mg/dL/hr). If glucose does not fall by at least 3.0 mmol/L in the first hour, verify IV access, and double the hourly insulin infusion rate.
• Subcutaneous Protocol (If Syringe Pumps Unavailable): Administer Regular Insulin 0.2–0.3 units/kg subcutaneous loading dose, followed by 0.1 units/kg subcutaneous every 1 hour (or 0.2 units/kg every 2 hours).

Pillar 3: Potassium Management Protocol

Insulin promotes rapid shift of potassium from the extracellular space into cells via the $Na^+/K^+$-ATPase pump. Concurrent fluid expansion dilutes serum potassium, and osmotic diuresis causes ongoing urinary potassium wasting. Serum potassium can crash precipitously:

+-----------------------------------------------------------------------------------+
|                         DKA POTASSIUM REPLACEMENT ALGORITHM                       |
+-----------------------------------------------------------------------------------+
| Serum Potassium (mmol/L) | Action Required                                        |
+--------------------------+--------------------------------------------------------+
| < 3.3 mmol/L             | HOLD INSULIN! Administer 20-40 mEq KCl/hour IV in saline|
|                          | until K+ rises above 3.3 mmol/L. Only then start insulin|
+--------------------------+--------------------------------------------------------+
| 3.5 - 5.0 mmol/L         | Add 20-30 mEq KCl per liter of IV replacement fluid.    |
|                          | Maintain serum K+ strictly between 4.0 and 5.0 mmol/L. |
+--------------------------+--------------------------------------------------------+
| > 5.0 mmol/L             | Do NOT add KCl to IV fluids. Check serum K+ every 2h.  |
|                          | Initiate potassium replacement when K+ drops < 5.0     |
+-----------------------------------------------------------------------------------+

Pillar 4: Criteria for Resolution of DKA and Transition to Subcutaneous Insulin

DKA is resolved only when all the following criteria are documented:

1. Blood glucose $< 11.1\text{ mmol/L}$ ($< 200\text{ mg/dL}$).
2. Venous blood $pH > 7.30$ or serum bicarbonate $\ge 18\text{ mmol/L}$.
3. Anion gap normalized ($\le 12\text{ mEq/L}$).
4. Patient is alert, hemodynamically stable, and tolerating oral nutrition.

• Mandatory Transition Rule: Administer a subcutaneous dose of basal insulin (e.g., NPH or Glargine) 1 to 2 hours prior to discontinuing the intravenous insulin infusion. Intravenous regular insulin has a half-life of only 5 to 9 minutes; stopping the infusion without subcutaneous overlap triggers rebound ketoacidosis within 30 to 60 minutes.

---

5. Thyroid Disorders & Endocrine Emergencies

Graves' Disease & Hyperthyroidism

Graves' disease is an autoimmune disorder driven by autoantibodies against the thyrotropin receptor (TRAb / thyroid-stimulating immunoglobulin [TSI]), resulting in autonomous excess synthesis and secretion of thyroid hormones ($T_3$ and $T_4$).

• Clinical Presentation: Weight loss despite increased appetite, heat intolerance, warm moist skin, fine resting tremor, sinus tachycardia or atrial fibrillation, proximal muscle weakness, hyperreflexia, and oligomenorrhea/amenorrhea. Pathognomonic extrathyroidal signs include Graves' orbitopathy (exophthalmos, periorbital edema, lid lag, chemosis) and pretibial myxedema (non-pitting, violaceous infiltrative dermopathy over the shins).
• Diagnostic Laboratory Profile: Suppressed serum Thyroid-Stimulating Hormone ($\text{TSH} < 0.01\text{ mIU/L}$) accompanied by elevated free thyroxine ($\text{FT}_4$) and/or free triiodothyronine ($\text{FT}_3$). Diffuse vascular goiter with an audible thyroid bruit on physical examination.
• Pharmacological Management:
  • Carbimazole: Initiated at 15 to 40 mg PO daily in divided doses, titrated down as thyroid hormone levels normalize (maintenance 5–15 mg daily). Adverse Effect Alert: Agranulocytosis occurs in 0.2–0.5% of patients; advise every patient that if they develop a sudden fever, severe sore throat, or mouth ulcers, they must immediately stop carbimazole and present for an emergency Full Blood Count.
  • Propylthiouracil (PTU): 100–150 mg PO 8-hourly. The preferred antithyroid drug during the first trimester of pregnancy due to carbimazole/methimazole teratogenicity (aplasia cutis, choanal atresia). Beyond the first trimester, switch back to carbimazole due to PTU-induced severe fulminant hepatotoxicity.
  • Symptom Control: Propranolol 20–40 mg PO 8-hourly rapidly relieves tremor, palpitations, anxiety, and tachycardia by blocking peripheral beta-adrenergic receptors and weakly inhibiting peripheral $T_4$ to $T_3$ deiodination.

Thyroid Storm (Accelerated Hyperthyroidism)

Thyroid storm is a rare, life-threatening exacerbation of thyrotoxicosis precipitated by acute systemic stress (infection, emergency surgery, trauma, DKA, childbirth, or abrupt cessation of antithyroid medication). Characterized by multi-organ decompensation and mortality exceeding 20%.

• Diagnostic Recognition (Burch-Wartofsky Point Scale $\ge 45$): Severe hyperthermia (39.0–41.0°C), marked sinus tachycardia or atrial fibrillation ($HR > 140\text{ bpm}$), heart failure, agitation, acute delirium, psychosis, stupor, or coma, alongside severe vomiting, diarrhea, and jaundice.
• Stepwise Multimodal Resuscitation Protocol:

+-----------------------------------------------------------------------------------+
|                    THYROID STORM EMERGENCY MANAGEMENT SEQUENCE                    |
+-----------------------------------------------------------------------------------+
| Step 1: Beta-Blockade        | Propranolol 60-80 mg PO q4h or IV Esmolol /         |
|                              | Labetalol. Controls hyperadrenergic overdrive.     |
+------------------------------+-----------------------------------------------------+
| Step 2: Block New Synthesis  | Propylthiouracil (PTU) 500-1000 mg PO loading dose, |
|                              | then 250 mg q4h (preferred over carbimazole because |
|                              | PTU additionally inhibits peripheral T4-to-T3).     |
+------------------------------+-----------------------------------------------------+
| Step 3: Block Hormone Release| Lugol's Iodine 5-10 drops PO q8h OR Potassium Iodide|
| (CRITICAL TIMING RULE!)      | MANDATORY RULE: Administer AT LEAST 1 HOUR AFTER    |
|                              | the antithyroid drug! Giving iodine first supplies  |
|                              | substrate for massive new thyroid hormone synthesis.|
+------------------------------+-----------------------------------------------------+
| Step 4: Corticosteroid Therapy| Hydrocortisone 100 mg IV q8h (or Dexamethasone 2 mg)|
|                              | Blocks peripheral T4-to-T3 conversion and treats    |
|                              | potential relative adrenal exhaustion.              |
+------------------------------+-----------------------------------------------------+
| Step 5: Supportive Cooling   | Paracetamol and active cooling blankets. AVOID      |
|                              | ASPIRIN (displaces T4/T3 from TBG, worsening storm)!|
+-----------------------------------------------------------------------------------+

Primary Hypothyroidism & Myxedema Coma

• Primary Hypothyroidism: Chronic autoimmune thyroiditis (Hashimoto's disease) and severe endemic iodine deficiency are primary drivers. Diagnostic profile reveals elevated serum TSH with low free $T_4$. Manifests with fatigue, weight gain, cold intolerance, constipation, coarse dry skin, non-pitting periorbital puffiness, and delayed relaxation phase of deep tendon reflexes ('hung-up' reflexes).
  • Replacement Therapy: Levothyroxine (L-thyroxine) at a full replacement dose of 1.6 mcg/kg/day PO taken on an empty stomach 30–60 minutes before breakfast. In elderly patients or those with known coronary artery disease, start low (25 to 50 mcg daily) and titrate upward by 12.5–25 mcg every 6 to 8 weeks to avoid precipitating angina or arrhythmias. Monitor serum TSH every 6 to 8 weeks until euthyroid.
• Myxedema Coma: The end-stage, life-threatening decompensation of severe longstanding hypothyroidism. Presents with severe hypothermia ($< 35.0^\circ\text{C}$), altered mental state, bradycardia, hypoventilation (hypercapnic respiratory failure), hypotension, severe generalized non-pitting myxedematous edema, and profound hyponatremia.
  • Emergency Treatment: Immediate airway protection. Administer Hydrocortisone 100 mg IV 8-hourly FIRST before thyroid hormone replacement to prevent precipitating fatal acute adrenal crisis (accelerated clearance of cortisol induced by thyroid hormone in patients with concurrent autoimmune adrenal insufficiency). Administer Levothyroxine 300 to 500 mcg IV loading dose, followed by 50 to 100 mcg daily. Institute gentle, passive external rewarming with blankets (avoid active heating pads, which cause rapid peripheral vasodilation and vascular collapse).